VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX
January 24 2017 - 1:04AM
REGULATED INFORMATION
GHENT, Belgium, 24 January 2017 -
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today
announced, in accordance with Article 14 of the Belgian Law of 2
May 2007 regarding the publication of major shareholdings in
issuers whose securities are admitted to trading on a regulated
market (the "Transparency Law"), that it received a notification of
shareholdings from Van Herk Investments B.V.
The above shareholder notified Ablynx that it
has exceeded the 10% threshold on 19 January 2017 and now holds
6,148,362 Ablynx shares, representing 10.07% of the current
61,076,074 outstanding Ablynx shares, an increase from a former
position of 5.40% (August 2016).
Van Herk Investments B.V. is controlled by Mr.
A. van Herk in accordance with Articles 5 and 7 of the Dutch
Companies Code.
Full versions of all transparency notifications
are available on Ablynx website, under the section Investors.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies®, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck &
Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Marieke VermeerschDirector IR & Corporate
Communicationst: +32 (0)9 262 00 82m: +32 (0)479 49 06
03 e: marieke.vermeersch@ablynx.comFollow us on Twitter
@AblynxABLX
Ablynx media/analyst relationsFTI Consulting:Julia
Phillips, Brett Pollard, Mo Noonan, Matthew Mosst: +44 20 3727
1000e: ablynx@fticonsulting.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ad9a9547-5742-4564-a5fe-aeb173704865